PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Med
Prif Awduron: Majem, Margarita, Cobo, Manuel, Isla, Dolores, Marquez-Medina, Diego, Rodriguez-Abreu, Delvys, Casal-Rubio, Joaquín, Moran-Bueno, Teresa, Bernabé-Caro, Reyes, Pérez-Parente, Diego, Ruiz-Gracia, Pedro, Arroyo, Marta Marina, Paz-Ares, Luis
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2021
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036854/
https://ncbi.nlm.nih.gov/pubmed/33810441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10071365
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg